TY - JOUR
T1 - Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors
AU - Neuman, Heather B.
AU - Weiss, Jennifer M.
AU - Schrag, Deborah
AU - Ronk, Katie
AU - Havlena, Jeffrey
AU - LoConte, Noelle K.
AU - Smith, Maureen A.
AU - Greenberg, Caprice C.
N1 - Funding Information:
came from a Clinical Scholar Award from the Society of University Surgeons; an investigator-initiated pilot grant from the University of Wisconsin Carbone Cancer Center; Grant number P30 CA014520 from the National Cancer Institute with support to the University of Wisconsin Carbone Comprehensive Cancer Center (UWCCC); as well as the Health Innovation Program, the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research [Grant number UL1TR0000427 from the Clinical and Translational Science Award program of the National Center for Research Resources, NIH National Center for Advancing Translational Sciences (NCATS)] and the UW School of Medicine and Public Health from The Wisconsin Partnership Program. This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/ CCR921930-02 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.
Funding Information:
ACKNOWLEDGMENT This project was funded under Contract No. HHSA290201000006I from the Agency for Healthcare Research and Quality (AHRQ) as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. Further funding
PY - 2013
Y1 - 2013
N2 - Background. Although recommendations for breast cancer follow-up frequency exist, current follow-up guidelines are standardized, without consideration of individual patient characteristics. Some studies suggest oncologists are using these characteristics to tailor follow-up recommendations, but it is unclear how this is translating into practice. The objective of this study was to examine current patterns of oncologist breast cancer follow-up and determine the association between patient and tumor characteristics and follow-up frequency. Methods. The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify stage I-III breast cancer patients diagnosed 2000-2007 (n = 39,241). Oncologist follow-up visits were defined using Medicare specialty provider codes and the linked AMA Masterfile. Multinomial logistic regression determined the association between patient and tumor characteristics and oncologist follow-up visit frequency. Results. Younger age (p\0.001), positive nodes (p\0.001), estrogen receptor/progesterone receptor positivity (p\0.001), and increasing treatment intensity (p\0.001) were most strongly associated with more frequent follow-up. However, after accounting for these characteristics, significant variation in follow-up frequency was observed. In addition to patient factors, the number and types of oncologists involved in follow-up were associated with follow-up frequency (p\0.001). Types of oncologists providing follow-up varied, with medical oncologists the sole providers of follow-up for 19-51 % of breast cancer survivors. Overall, 58 % of patients received surgical oncology, and 51 % undergoing radiation received radiation oncology follow-up, usually in combination with medical oncology. Conclusions. Significant variation in breast cancer followup frequency exists. Developing follow-up guidelines tailored for patient, tumor, and treatment characteristics while also providing guidance on who should provide follow-up has the potential to increase clinical efficiency.
AB - Background. Although recommendations for breast cancer follow-up frequency exist, current follow-up guidelines are standardized, without consideration of individual patient characteristics. Some studies suggest oncologists are using these characteristics to tailor follow-up recommendations, but it is unclear how this is translating into practice. The objective of this study was to examine current patterns of oncologist breast cancer follow-up and determine the association between patient and tumor characteristics and follow-up frequency. Methods. The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify stage I-III breast cancer patients diagnosed 2000-2007 (n = 39,241). Oncologist follow-up visits were defined using Medicare specialty provider codes and the linked AMA Masterfile. Multinomial logistic regression determined the association between patient and tumor characteristics and oncologist follow-up visit frequency. Results. Younger age (p\0.001), positive nodes (p\0.001), estrogen receptor/progesterone receptor positivity (p\0.001), and increasing treatment intensity (p\0.001) were most strongly associated with more frequent follow-up. However, after accounting for these characteristics, significant variation in follow-up frequency was observed. In addition to patient factors, the number and types of oncologists involved in follow-up were associated with follow-up frequency (p\0.001). Types of oncologists providing follow-up varied, with medical oncologists the sole providers of follow-up for 19-51 % of breast cancer survivors. Overall, 58 % of patients received surgical oncology, and 51 % undergoing radiation received radiation oncology follow-up, usually in combination with medical oncology. Conclusions. Significant variation in breast cancer followup frequency exists. Developing follow-up guidelines tailored for patient, tumor, and treatment characteristics while also providing guidance on who should provide follow-up has the potential to increase clinical efficiency.
UR - http://www.scopus.com/inward/record.url?scp=84892364551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892364551&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-3170-8
DO - 10.1245/s10434-013-3170-8
M3 - Article
C2 - 23943027
AN - SCOPUS:84892364551
VL - 20
SP - 4128
EP - 4136
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 13
ER -